Is BPC-157 Legal? FDA Status, State Rules, Drug Testing

Key takeaways

• Possessing BPC-157 is not a crime: peptides are not controlled substances. Selling it for human use is illegal, because it is an unapproved drug, whatever the label says.
• No licensed US pharmacy may compound it in October 2026. It is not a component of an approved drug, has no USP monograph and is not on FDA's 503A bulks list, so a prescription for it cannot be legally filled.
• It left FDA's Category 2 list in April 2026, and FDA's advisory committee recommended it 8-6-1 in July 2026, but FDA has not proposed a rule. Recommended is not permitted.
• In sport it is prohibited at all times under WADA class S0, USADA says a therapeutic use exemption is unlikely, and from January 1, 2027 the List names peptides in general in S0. Anti-doping laboratories have a validated urine test.
• State law adds a layer of licensing for pharmacies and prescribers, but it does not change the federal list of what may be compounded, so it cannot make BPC-157 compoundable.

Is BPC-157 legal? Partly, and the part that matters most is no. In October 2026 BPC-157 is legal to possess, because it is not a controlled substance; it is not FDA-approved; no licensed US pharmacy may compound it; selling it for human use is illegal; and it is prohibited at all times in tested sport. This page explains each answer. How FDA's compounding categories work is in our parent guide, FDA Category 2 peptides explained; what the 2026 headlines did and did not change is in the FDA peptide ban, explained; and the status of every other peptide is in the legal tracker.

BPC-157 legal status at a glance

Federal status: three tests, one vote, no rule

A licensed pharmacy may compound only from a bulk ingredient that has a USP monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list (FDA 503A). BPC-157 passes none of the three. That is the whole legal problem, and nothing in 2026 has changed it yet.

What did change is FDA's safety flag. FDA placed BPC-157 in Category 2 in September 2023, stating that compounded BPC-157 may pose a risk of immune reactions, has impurity and characterization problems, and that FDA had "no, or only limited, safety-related information" for the proposed routes. FDA still publishes that statement, now on its list of substances whose nominations were withdrawn (FDA Category 2). The withdrawal, announced April 15, 2026, ended the flag. It did not put BPC-157 on the permitted list, and it did not place it in Category 1, the only category FDA tolerates compounding from while it evaluates.

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee considered BPC-157 for one use, ulcerative colitis (Federal Register 2026), and voted 8 to 6 with one abstention to recommend it, over the objection of FDA's reviewers, who said the products on the market vary in amino-acid count and have no settled salt or free-base form (HPM 2026). The vote is advisory. FDA must publish a proposed rule, take comments and finalize it before any pharmacy may use BPC-157. Our search of the Federal Register on October 10, 2026 found no proposed rule. The BPC-157 profile has the evidence that was in front of the committee: animal studies and three uncontrolled human pilots.

Can you get a BPC-157 prescription?

You can find a clinician who will write one; telehealth sites advertise it. But a prescription is an instruction to a pharmacy, and no licensed pharmacy may fill this one. A service that "prescribes" BPC-157 is either attaching a consultation to a research vial or using a pharmacy that is operating outside federal law. The question that sorts this out is the tracker's: which pharmacy, in which state, 503A or 503B, and on what legal basis is BPC-157 compoundable? In October 2026 there is no good answer.

A legal compounded peptide comes with a pharmacy label stating its concentration, which is what our peptide calculator is built to read. BPC-157 has no label and no studied human dose, so there is nothing legitimate to calculate; FDA's 2026 warning letters even cited calculators on vendor websites as evidence of sale for human use, as the FDA peptide ban explainer describes.

Possession versus sale

Possession. Peptides are not scheduled under the Controlled Substances Act. Possessing a vial of BPC-157 is not a crime, and no one is prosecuted for injecting one. The one exception that behaves like a controlled substance is human growth hormone, a different drug with its own federal statute, which the tracker explains.

Sale. Selling BPC-157 for human use is selling an unapproved drug, which federal law prohibits. A "research use only" or "not for human consumption" label does not change that when the seller's website gives dosing guidance, injection instructions or bundled supplies. FDA's 2026 warning letters made that point to research-peptide vendors; the letters we have tracked named GLP-1 drugs and other peptides rather than BPC-157, but the reasoning applies to any peptide sold the same way. The letters went to sellers, not buyers.

Importing. Ordering an unapproved drug from overseas for personal use is generally not permitted, and FDA may detain it.

In sport, possession is enough. Anti-doping rules treat possession as a violation in itself. In September 2025, USADA announced a four-year ban for a triathlete after a whistleblower tip and an investigation found he had possessed and used BPC-157 and TB-500 and promoted prohibited peptides to followers on social media; USADA classed BPC-157 as a Specified Substance among non-approved substances (USADA 2025).

State rules

State law sits on top of the federal answer and cannot change it. States license the pharmacies that compound and the clinicians who prescribe; a prescription is valid only from a clinician licensed in the state where you are at the time of the visit. None of that alters the federal list of what may be compounded.

Florida shows what the state layer looks like. Any out-of-state pharmacy or outsourcing facility that ships a compounded sterile product into Florida must hold a Florida nonresident sterile compounding permit, attest that its products meet Florida's sterile compounding standards, and may not ship anything compounded in violation of the laws of its home state (Fla. Stat. 465.0158). Rules like that make a legitimate compounded injection more accountable. They do nothing for BPC-157, which no pharmacy may compound in the first place.

Louisiana is the one state we know of with a 2026 law on peptides. Senate Bill 253 was signed on May 22, 2026 as Act 374 and took effect on August 1, 2026 (Louisiana SB 253). We read the enrolled act on October 12, 2026. It bars licensing boards from prohibiting a prescriber from providing patients with peptides shipped from an FDA-registered 503B outsourcing facility in compliance with 21 U.S.C. 353b or a 503A pharmacy in compliance with 21 U.S.C. 353a and the applicable USP-NF chapters, and bars boards from prohibiting a Louisiana pharmacist in a permitted pharmacy from compounding and dispensing peptides under those same federal conditions. Every protection is conditioned on federal compliance, so the act does not make BPC-157 compoundable in Louisiana or anywhere else. Otherwise we report state rules on BPC-157 only when we can read them in a state's own statutes or board rules, and as of October 10, 2026 we have none that changes the answer above. Before you act on anything a clinic says about your state, check your state board of pharmacy's license lookup for the pharmacy it names, and read how online peptide prescribing works state by state.

Drug testing: sport and work

Anti-doping tests. USADA states that BPC-157 is prohibited under the WADA Prohibited List in class S0, non-approved substances, and that it is not approved for human clinical use by FDA or any other health authority. It adds that a therapeutic use exemption is unlikely to be approved because permitted alternatives exist (USADA BPC-157). S0 substances are prohibited at all times, in and out of competition. The rules are tightening: USADA's advisory on the 2027 List says that from January 1, 2027, peptides in general are named as prohibited in S0, lists BPC-157 first among the examples alongside TB-500, AOD-9604, GHRPs, ipamorelin, ibutamoren and IGF-1 analogues, and warns that a peptide missing from the List may still be prohibited because athletes are strictly liable for what is in their bodies (USADA 2027).

Testing is real. After BPC-157 turned up in confiscated vials, the Salt Lake City anti-doping laboratory validated a urine method with a detection limit of 0.1 ng/mL, found the peptide stable in urine for at least four days, and identified a metabolite that improves specificity (Cox 2017). How many days after a dose a test stays positive has not been established; our BPC-157 side effects page covers what is and is not known.

Workplace tests. Federally regulated tests, such as those for transportation workers, cover five drug classes, and laboratories must not test those specimens for any other drug (49 CFR 40.82). Private employers choose their own panels; as far as we know, none of the standard panels includes BPC-157. A research vial could also contain something other than what its label says.

Bottom line

BPC-157 is legal to own and illegal to sell for human use, and in October 2026 there is no legal way to get it from a pharmacy. The April 2026 Category 2 removal and the July 2026 committee vote moved it closer to the permitted list without putting it there, and FDA's reviewers remain opposed. If you compete in tested sport, it is banned at all times, and from 2027 the List names peptides as a class. If a clinic tells you otherwise, ask it to name the pharmacy and the legal basis, and check the tracker, which we update the day FDA acts.

Frequently asked questions

+−Is BPC-157 legal in the US?

It is legal to possess, because peptides are not controlled substances. It is not FDA-approved, no licensed US pharmacy may compound it as of October 2026, and selling it for human use is illegal because it is an unapproved drug, whatever the label says. It is also prohibited at all times in sport under WADA class S0.

+−Is BPC-157 FDA approved?

No. It has never been approved in any country, and it has never been a component of an approved drug. USADA notes that it is not approved for human clinical use by FDA or any other health authority.

+−Can I get a BPC-157 prescription online?

A clinician can write one, but no licensed US pharmacy may legally fill it in October 2026, because BPC-157 passes none of the three tests in federal compounding law. Telehealth sites that offer BPC-157 prescriptions are attaching a consultation to a research vial, or using a pharmacy that is breaking the rules. Ask which pharmacy, in which state, and on what legal basis.

+−Is it illegal to buy BPC-157 online?

Buying or possessing it is not a crime, because it is not a controlled substance. The law acts on the seller: selling an unapproved drug for human use is illegal, and a research-use-only label does not protect a seller whose website shows the product is meant for people. Importing an unapproved drug for personal use is generally not permitted, and FDA may detain the package.

+−Does BPC-157 show up on a drug test?

On an anti-doping test, it can: an anti-doping laboratory validated a urine method in 2017 that detects BPC-157 at 0.1 ng/mL and measures a stable metabolite. On a federally regulated workplace test, no: those tests are limited by rule to five drug classes, and laboratories may not test those specimens for anything else.

+−Is BPC-157 banned in sports?

Yes. USADA says it is prohibited under WADA class S0, non-approved substances, which are prohibited at all times, and that a therapeutic use exemption is unlikely because permitted alternatives exist. From January 1, 2027 the WADA List names peptides in general in S0. In 2025 USADA imposed a four-year ban on a triathlete for possessing and using BPC-157 and TB-500 and promoting prohibited peptides.

+−Did FDA approve BPC-157 in 2026?

No. FDA removed it from its Category 2 safety-risk list on April 15, 2026 after its nomination was withdrawn, and FDA's advisory committee voted 8 to 6, with one abstention, on July 23, 2026 to recommend adding it to the list of substances pharmacies may compound. The vote is advisory, FDA's reviewers had recommended against it, and as of October 10, 2026 FDA has not published a proposed rule.

+−Is it illegal to sell BPC-157?

Selling it for human use is. BPC-157 is an unapproved drug, and introducing an unapproved new drug into interstate commerce violates the Federal Food, Drug, and Cosmetic Act. FDA's 2026 warning letters to peptide vendors rejected research-use-only labels when the websites gave dosing guidance, injection instructions or calculators.

Sources

1. RegulatoryFDA. Certain bulk drug substances for use in compounding that may present significant safety risks: Category 2, and substances nominated but withdrawn, including BPC-157 (content current as of April 22, 2026). Read October 10, 2026. (2026)
2. RegulatoryFDA. Bulk drug substances used in compounding under section 503A of the FD&C Act: the three legal tests and the interim policy categories (content current as of May 14, 2026). Read October 10, 2026. (2026)
3. RegulatoryFederal Register. Pharmacy Compounding Advisory Committee; notice of meeting (July 23-24, 2026): BPC-157 (free base and acetate) to be discussed for ulcerative colitis. April 16, 2026. (2026)
4. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
5. GuidelineUS Anti-Doping Agency. BPC-157: what athletes should know about the prohibited experimental peptide (S0 non-approved substances; TUE unlikely). Published March 3, 2020, updated August 10, 2026; read October 10, 2026. (2026)
6. GuidelineUS Anti-Doping Agency. Athlete advisory: what's new on the 2027 WADA Prohibited List (peptides in general named in S0; effective January 1, 2027). Read October 10, 2026. (2026)
7. NewsUS Anti-Doping Agency. Triathlon athlete accepts sanction for anti-doping rule violations (possession and use of BPC-157 and TB-500; four-year period of ineligibility). September 17, 2025. (2025)
8. StudyCox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017;9:1490-8. (2017)
9. Regulatory49 CFR 40.82, What drugs do laboratories test for? (DOT workplace testing: five drug classes; laboratories must not test DOT specimens for any other drugs). Legal Information Institute, Cornell Law School, read October 10, 2026.
10. RegulatoryFlorida Statutes 465.0158: nonresident sterile compounding permit. Florida Legislature, Online Sunshine, read October 10, 2026. (2026)
11. RegulatoryLouisiana Legislature. SB 253 (2026 Regular Session), signed by the Governor May 22, 2026 as Act 374, effective August 1, 2026 (public health: provides relative to peptides). Enrolled act (2 pages, enacting R.S. 37:23.5) read October 12, 2026. (2026)